替米沙坦对高血压合并冠心病患者心功能及炎性因子的影响

目的探讨替米沙坦对高血压合并冠心病患者心功能及炎性因子的影响。方法将126例高血压合并冠心病患者随机分为对照组与观察组,对照组60例患者给予硝苯地平缓释片降压,观察组66例给予替米沙坦口服,疗程均为6个月,比较治疗前后两组患者血压、心功能及炎性因子的改变。结果治疗后6个月两组收缩压及舒张压均无显著差别(P>0.05);观察组左室射血分数(LVEF)、心脏指数(CI)及心脏舒张功能指标E/A比值显著优于对照组(P<0.05);观察组治疗后血清超敏C-反应蛋白(hs-CRP)、肿瘤坏死因子-α(TNF-α)及白细胞介素-6(IL-6)显著低于对照组(P<0.05)。结论替米沙坦可显著减少高血压合并冠心病患者血清炎症因子水平,改善患者心功能及左室重塑,有利于改善患者预后。

Influence of telmisartan on cardiac function and inflammatory factors in hypertension combining coronary heart disease patients

Objective To explore the influence of telmisartan on cardiac function and inflammatory factors in hypertension combining coronary heart disease patients. Methods All 126 cases with hypertension combining coronary heart disease were randomly divided into control group and experience group. 60 cases of control group were given sustained-release nifedipine treatments and 66 patients of experience group received telmisartan treatment. Blood pressure, cardiac function and inflammatory factors before and after treatment were compared between two groups. Results There were no significant difference of blood pressure 6 months after treatment between two groups （P 〉 0.05）; LVEF, CI and E/A in experience group were superior to that in control group （P 〈 0.05） ; Hs-CRP, TNF-ctand IL-6 after treatment in experience group were much lower than that in control group （P 〈 0.05）. Conclusion Telmisartan can greatly decrease the inflammatory factors level in hypertension combining coronary heart disease patients, and improve the patients＇ cardiac function, left ventrieular remodeling and prognosis.